GTX (GTXI) Stock Price, News & Analysis

Company Overview

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Key Stats

• Today's Range: $1.06 to $1.14
• 50-Day Range: $1.20 to $7.20
• 52-Week Range: $0.74 to $25.60
• Volume: 26,256 shs
• Average Volume: 390,540 shs
• Market Capitalization: $27.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GTXI Stock Analysis - Frequently Asked Questions

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09.

What other stocks do shareholders of GTX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GTX investors own include Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), SELLAS Life Sciences Group (SLS), Verastem (VSTM), Bristol-Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 11/15/2018
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GTXI
• CUSIP: 40052B10
• CIK: 1260990
• Web: www.gtxinc.com
• Phone: 901-523-9700
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-38,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -104.19%
• Return on Assets: -86.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.39
• Quick Ratio: 12.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.09 per share
• Price / Book: 1.05

Miscellaneous

• Outstanding Shares: 24,050,000
• Free Float: N/A
• Market Cap: $27.42 million
• Optionable: Not Optionable
• Beta: 2.22